Table 2. Migraine Characteristics and Physiological Effects in Participants Undergoing Randomized, Double-Blind, Placebo-Controlled, Crossover Trials With 2-Hour Intravenous Infusion of VIP.
| Incidence | No. (%) | |
|---|---|---|
| Patients with migraine (n = 21) | Healthy volunteers (n = 12)a | |
| Migraine attack | 15 (71) | 3 (25) |
| Nausea | 18 (86) | 4 (33) |
| Photophobia | 12 (57) | 1 (8) |
| Phonophobia | 9 (43) | 0 |
| Flushing | 20 (95) | 12 (100) |
| Warm sensation | 20 (95) | 12 (100) |
| Heart palpitation | 17 (81) | 12 (100) |
Abbreviation: VIP, vasoactive intestinal polypeptide.
a
Data were previously published in Pellesi et al.19